Gsk Share Discussion Threads

[pierre oreilly] 12/8/2022 14:58

Spot on careful.

It's the same antics of bb shorters but while bb shorters have no effect on big companies, the city lot can, by backing their antics with hundreds of millions.

[pierre oreilly] 12/8/2022 14:40

jON, Wow thanks. I'd like to claim to be a wizz trader, but i'm afraid buys like that are purely down to luck. I sold half my holding some weeks before the split, so it was easy to buy back if the price crashed. Shame about the other half i held! I'm not a trader, but i know that overreaction both up and down is common, and such corporate actions virtually never live up to expectations in the short term. The claim situation i think is overblown - drug companies continually face all sorts of claims and they are given prominence when some outfit wants to short a lot.

[alphorn] 12/8/2022 14:12

I forgot that GSK sold off Tagamet to Prestige Consumer Healthcare a few years ago, so that route is no longer available. Worth remembering that Tagamet was the world's first 'blockbuster' drug.

[dr biotech] 12/8/2022 13:58

Alphorn, TM is correct - it’s the structure and instability of the molecule that makes NDMA - so Tagamet shouldn’t be affected. However It may be present in other drugs due to the manufacturing process, not sure if that applies. So it will always be present in ranitidine, though it may be more stable as a parenteral. It’s explained in more detail in the link in TMs earlier post.



Looking at the HPLC data the level of NDMA is minuscule, I’m not surprised this wasn’t picked up for decades.

[spoole5] 12/8/2022 13:50

Amazing how this and HLN have been manipulated, bet quite a few PIs have been suckered out of their holdings on the cheap.

[spyder] 12/8/2022 13:44

—>Alphorn & Dr B
I think Scott Gottlieb (ex FDA Commissioner) mentioned in his CNBC interview that trace NDMA was first detected in a blood pressure drug. It is definitely an issue with other drugs.
This really seems like a non-issue as far as most scientific bods are concerned.

[jonjoneil] 12/8/2022 13:39

Pierre Oreilly
Good call yesterday. Credit where credit's due

[tradermichael] 12/8/2022 12:28

Alphorn, the reactivity of the molecule and its chemical structure are key to any instability giving rise to this impurity

[alphorn] 12/8/2022 11:35

DrB - I presume that GSK is still selling cimetidine (Tagamet), ex SKB, in the same space? (Although it seems that the same issue has been raised with that drug?)

edit: I wonder if this a general manufacturing process with other drugs? Outside of my knowledge.

[dr biotech] 12/8/2022 11:26

The CHMP, having reviewed the grounds from the MAH and the available clinical safety data confirmed its previous position that there is no evidence of a causal association between ranitidine therapy and the development of cancer in patients and that therefore the corresponding statement does not need to be changed. However, any potential cancer risk due to NDMA exposure associated with ranitidine use is of a low level and will probably not be detected with conventional animal studies or epidemiological studies. Whilst epidemiological or clinical trial data did not indicate an increased risk of cancer in humans after the use of ranitidine, a theoretical risk cannot be excluded.


Conclusion is that ranitidine may get (re)approval for single dose but not lifetime dose.

Again I think it will be very hard to prove taking Zantac caused illness. Just no evidence.

[spranson] 12/8/2022 11:13

Changed your tune since post 30405 halfpenny

"GSK will see further falls. Too Risky at this level. The point is that the traces found in the Drug should not have been there in the first place. This is why USA authorities will penalise GSK big time!!
halfpenny - 11 Aug 2022 - 13:27:56 - 30402 of 30488
The point is that the traces found in the Drug should not have been there in the first place. This is why USA authorities will penalise GSK big time!!"

[halfpenny] 12/8/2022 10:50

Its a non issue so I am topping up as we will have a sharp rise. GSK is being recommended by brokers and 1850 on the way soon. Fill Ya Boots if you can before a rapid rise. Directors will also be buying.

[tradermichael] 12/8/2022 10:09

qip: this is going to court in the next couple of weeks:

[cerrito] 12/8/2022 10:02

It is correct to say that Pfizer said quote we believe at this time that the outcome of the litigation is not likely to be material to Pfizer.
unquote but my reading of their statement is that this was based on issues specific to Pfizer including fact that stopped selling Zantac in 2006 rather those that could affect GSK.

[nimbo1] 12/8/2022 09:42

bought some gsk following todays update. on a tight leash. fingers crossed

[qipincha] 12/8/2022 09:28

what happened recently?

[netcurtains] 12/8/2022 09:13

redbaron10: They are plonkers.
This is going up!

[geckotheglorious] 12/8/2022 09:06

Comments from Co Defendant

Pfizer says impact of Zantac litigation is unlikely to be material

After a ~3% decline in its share price on Thursday amid concerns over the legal overhang related to recalled heartburn medication Zantac, Pfizer (NYSE:PFE) has sought to rule out a significant impact from the litigation.

[redbaron10] 12/8/2022 09:04

These sellers and shorters are on the other side of the trade you're making as a buyer /investor.Don't make the mistake of thinking they're 'totally bonkers' otherwise your career/hobby as an investor is going to be short lived.They're out to make money as you're trying to do.

[netcurtains] 12/8/2022 08:54

Redbaron10: Why are you telling people to do their own research then in the very next sentence, tell them what to do?????

ALl these sellers and shorters are just totally bonkers.

[redbaron10] 12/8/2022 08:51

Dyor....weigh your risk/reward investment metrics and either buy long term or leave alone.Simples.Unless you like trading stocks where you do your own thing.

[netcurtains] 12/8/2022 08:49

But why?
Huge profits,
Good portfolio of drugs coming through
low PE
Its all good.

[montyhedge] 12/8/2022 08:48

Not really, this is a dead cat bounce.

[netcurtains] 12/8/2022 08:47

really surprised this has not bounced back to 1600, or at least 1500.
How weird.

[spyder] 12/8/2022 08:45

—> all
Anyone out there who has access to analysts notes? Were the analysts considering the Zantac risk when they were setting their price targets that mostly ranged from £17 - £23?
It seems odd that this (‘old’) news seems to have taken the market by surprise? What has changed? There is a massive amount of public domain info on this, why has the market suddenly reacted in this way or is this just August madness?